Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Why this talk

<< Previous

Bullboard Posts

Next >>

Comment by woundedkneeon Apr 23, 2021 8:55am

96 Views

Post# 33054043

RE:RE:Why this talk

If new investors haven't done their DD on Antibe yet then I would suggest Dan is not doing a very good job. And by the way, I thought we were paying an IR firm thousands a month to do just that. Attract new investors, that is. So if it has been turned over to Dan let's terminate the IR contract and save a few bucks.

<< Previous

Bullboard Posts

Next >>

Southern Ontario mineral processing operation receives green fund support